Comparative Analysis of Enobosarm (MK-2866) and Ligandrol (LGD-4033)

Abstract

Selective Androgen Receptor Modulators (SARMs) represent a class of therapeutic compounds designed to elicit the anabolic benefits of traditional androgenic anabolic steroids (AAS) while minimizing adverse effects on non-target tissues (e.g., prostate and sebaceous glands). Enobosarm (Ostarine/MK-2866) and Ligandrol (LGD-4033) are the two most extensively studied non-steroidal SARMs in human clinical trials. While both compounds target the androgen receptor (AR) with high affinity to promote lean body mass (LBM) and bone mineral density, they differ in potency, clinical application focus, and pharmacokinetic profiles. This article compares the two compounds based on published clinical data, emphasizing their efficacy in muscle preservation and their respective safety profiles.

Mechanism Comparison

Both Enobosarm and Ligandrol are non-steroidal ligands that bind to the AR, inducing a conformational change that promotes tissue-specific gene expression.

• •Enobosarm (MK-2866): Functions as a full agonist in skeletal muscle and bone but exhibits restricted activity in the prostate. It does not undergo conversion to dihydrotestosterone (DHT) via 5-alpha reductase, nor does it aromatize into estrogen. Its selectivity is characterized by its ability to stimulate protein synthesis and satellite cell proliferation without significant androgenic stimulation of secondary sexual characteristics.
• •Ligandrol (LGD-4033): Demonstrates an exceptionally high binding affinity (Ki of ~1 nM). Like Enobosarm, it is tissue-selective and avoids 5-alpha reduction and aromatization. However, LGD-4033 is generally considered more potent on a milligram-for-milligram basis regarding AR activation in muscle tissue, leading to more pronounced anabolic signals at lower dosages compared to Enobosarm.

Efficacy Comparison

Evidence for efficacy is derived from Phase I and Phase II human clinical trials focusing on lean body mass (LBM) and physical function.

| Feature | Enobosarm (MK-2866) | Ligandrol (LGD-4033) | | :--- | :--- | :--- | | Primary Clinical Focus | Cancer cachexia, sarcopenia, stress urinary incontinence. | Sarcopenia, hip fracture recovery. | | LBM Increase (Human) | ~1.3 kg (3 mg dose for 12 weeks) | ~1.21 kg (1.0 mg dose for 21 days) | | Potency | Moderate; therapeutic doses range 1–3 mg. | High; therapeutic doses range 0.1–1 mg. | | Physical Function | Significant improvement in stair climb power. | Dose-dependent improvement in leg press strength. |

Enobosarm Data: In a pivotal Phase II double-blind, placebo-controlled study of 120 healthy elderly men and women, 3 mg of Enobosarm daily for 12 weeks resulted in a significant increase in LBM (median 1.3 kg) compared to placebo (Dalton et al., 2011).

Ligandrol Data: In a Phase I multiple ascending dose study, 76 healthy men received doses of 0.1, 0.3, or 1.0 mg of LGD-4033. The 1.0 mg group gained 1.21 kg of LBM in just 21 days (Basaria et al., 2013). This suggests LGD-4033 may induce muscle accretion more rapidly than Enobosarm at lower absolute doses.

Safety & Side Effect Comparison

Both compounds are generally well-tolerated in clinical settings but share a distinct profile of secondary effects related to the endocrine and lipid systems.

1. •

   Hormonal Suppression:

   • •Enobosarm: Dose-dependent reductions in total testosterone and Sex Hormone-Binding Globulin (SHBG) were observed. However, no significant changes in Luteinizing Hormone (LH) or Follicle-Stimulating Hormone (FSH) were noted at therapeutic doses (3 mg), suggesting less hypothalamic-pituitary-gonadal (HPG) axis disruption than AAS (Dobs et al., 2013).
   • •Ligandrol: Significant dose-dependent suppression of total testosterone, SHBG, and HDL cholesterol was observed. At 1.0 mg, testosterone levels were suppressed by approximately 40% from baseline, though they returned to normal within 56 days post-treatment (Basaria et al., 2013).
2. •

   Lipids:

   • •Both compounds consistently lower High-Density Lipoprotein (HDL) cholesterol. In the Basaria et al. study, LGD-4033 at 1.0 mg reduced HDL by nearly 40%. Enobosarm showed similar, though slightly less aggressive, lipid-altering effects at the 3 mg dose (Dalton et al., 2011).
3. •

   Hepatotoxicity:

   • •Transient elevations in liver enzymes (ALT/AST) have been observed with both compounds in clinical trials, but levels typically remained within the upper limit of normal or resolved without intervention. Case reports of higher-dose "gray market" use have suggested a risk of drug-induced liver injury (DILI), though this is not reflected in controlled low-dose clinical trials (Koller et al., 2021).

Pharmacokinetics Comparison

• •Enobosarm: Exhibits an elimination half-life of approximately 24 hours, making it suitable for once-daily oral dosing. It reaches steady-state plasma concentrations within one week of administration.
• •Ligandrol: Displays a longer elimination half-life of approximately 24 to 36 hours. Like Enobosarm, it possesses high oral bioavailability. Due to the longer half-life, plasma accumulation is slightly more pronounced over a 21-day period (Basaria et al., 2013).

Research Limitations

1. •Duration: Most human clinical trials for SARMs do not exceed 12 weeks. The long-term safety profile (years of use) is currently unknown.
2. •Lack of Head-to-Head Trials: There are no published peer-reviewed human studies that directly compare Enobosarm and Ligandrol in the same cohort. Comparisons are currently limited to cross-study analysis.
3. •Regulatory Status: Neither compound is currently FDA-approved for any indication. Much of the data available stems from "gray market" use, which often involves much higher doses than those tested in clinical trials, potentially leading to more severe side effects.

References

1. •Basaria, S., et al. (2013). The safety and pharmacokinetics of LGD-4033, a novel nonsteroidal oral selective androgen receptor modulator, in healthy young men. The Journals of Gerontology: Series A, 68(1), 87-95. DOI: 10.1093/gerona/gls078
2. •Dalton, J. T., et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. The Lancet Oncology, 12(9), 854-862. DOI: 10.1016/S1470-2045(11)70153-8
3. •Dobs, A. S., et al. (2013). Effects of enobosarm on muscle mass and physical function in patients with cancer: a double-blind, randomised, controlled phase 2 trial. The Lancet Oncology, 14(4), 335-345. DOI: 10.1016/S1470-2045(13)70055-X
4. •Koller, T., et al. (2021). Drug-induced liver injury associated with the use of selective androgen receptor modulators. Cureus, 13(2). DOI: 10.7759/cureus.13575
5. •Taylor, H. S., et al. (2022). VK5211 for recovery from hip fracture: A Phase 2, randomized, placebo-controlled trial. Journal of Cachexia, Sarcopenia and Muscle, 13(2), 940-951. (Note: VK5211 is the pharmaceutical designation for LGD-4033). DOI: 10.1002/jcsm.12932